Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity.

ABSTRACT:

Background

Variations in single nucleotide polymorphisms (SNPs) have been associated with enhanced drug efficacy and toxicity in cancer therapy. SNP variations in the ErbB2 gene have been identified that alter the protein sequence of the HER2-neu protein, but how these polymorphisms affect prognosis and response to HER2 targeted therapy is unknown. We examined eleven ErbB2 SNPs that alter the HER2-neu amino acid sequence to determine whether any of these particular polymorphisms were associated with increased trastuzumab cardiotoxicity in a case-control study.

Methods

140 subjects were enrolled from a single institution under Weill Cornell Medical College IRB protocol #0804009734. Patients were eligible if they had histologically or cytologically proven HER2-neu positive bre

SUBMITTER: Stanton SE 

PROVIDER: S-EPMC4403678 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature